Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...

The U.S. Food and Drug Administration (FDA) on Wednesday approved Omeros Corporation (NASDAQ: OMER) Yartemlea ...

Omeros on Wednesday said the approval covers Yartemlea for patients ages 2 and older with hematopoietic stem-cell transplant-associated thrombotic microangiopathy, a complication driven by the ...

Omeros Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated ...

Omeros (OMER) announced that the U.S. Food and Drug Administration, FDA, has approved YARTEMLE for the treatment of hematopoietic stem cell ...

Many novel treatment approaches are being investigated to halt progression of geographic atrophy (GA) or, potentially, even reverse the retinal damage. The major categories include novel complement ...

Novo Nordisk A/S has acquired Zaltenibart, a Phase 2 MASP-3 inhibitor, for up to $2.1 billion, signaling strong conviction in its long-term potential. NVO shares have declined ~20% since October, now ...

Many have sought to revitalize the accounting profession by attracting a new generation of tech-savvy young professionals ...

LONE TREE, Colo. — As fewer people go to school to be teachers and many leave the profession altogether, school districts are turning to alternative pathways to bring new teachers into classrooms. "I ...

As fewer people go to school to be teachers and many leave the profession altogether, districts are turning to new options to bring new teachers into classrooms. Questions swirl around Donald Trump, ...

Texas will become the 13th state to offer an alternative licensure pathway for experienced international physicians this September, The Dallas Morning News reported Aug. 13. House Bill 2038 — called ...